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Summary  
This study reviewed outcomes from 83 rectal cancer patients treated with CXB boost for 
residual tumour ≤ 3cm following EBRT. Fifty three (63.8%) patients achieved cCR. Local 
regrowth after cCR was low at 11.3%. All patients had successful salvage surgery. At median 
follow-up of 2.5 years, 63 (83.1%) patients were cancer free. This approach may provide a 
non-surgical treatment option to reduce local regrowth after EBCRT in patients not suitable 
or wish to avoid surgery. 
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Abstract 
Purpose  
To review the outcomes of rectal cancer patients treated with a non-surgical approach using 
contact X-ray brachytherapy (CXB) when there was suspicious residual disease (≤3 cm) 
following external beam chemoradiotherapy/radiotherapy (EBCRT/EBRT). 
 
Methods and materials 
Outcome data for rectal cancer patients referred to our institution from 2003 to 2012 were 
retrieved from an institutional database. These patients were referred after initial local 
multidisciplinary team discussion either because they were not suitable for or refused surgery. 
All selected patients had a CXB boost following EBCRT/EBRT. Most patients received a total 
of 90Gy CXB delivered in three fractions over 4 weeks.  
 
Results 
The median follow up was 2.5 years (range 1.2-8.3 years). Of 345 consecutive patients with 
rectal cancer who were referred to us, 83 patients with suspicious residual disease (≤3 cm) after 
EBCRT/EBRT were identified for CXB boost. Median age was 72 years (range 36–87) and 58 
(69.9%) were males. Initial tumor stages were cT2 (n=28), cT3 (n=55) and 54.2% were node 
positive. Complete clinical response (cCR) was achieved in 53 (63.8%) patients after the CXB 
boost following EBCRT/EBRT. Seven (13.2%) of these 53 patients relapsed after achieving 
cCR and the six patients (11.6%) who had non-metastatic regrowth had salvage surgery 
(100%). At the end of the study period, 69 (83.1%) out of 83 patients were cancer free.  
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Conclusions 
Our data suggest that a CXB boost in selected patients with suspicious residual disease (≤3 
cm) following EBCRT/EBRT can be offered as an alternative to radical surgery. In our series 
patients with a sustained cCR had a low rate of local regrowth and those with non-metastatic 
regrowth could be salvaged successfully. This approach could provide an alternative 
treatment option for elderly or comorbid patients who are not suitable for surgery, or those 
with rectal cancer who wish to avoid surgery.  
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Introduction  
Although a decade ago, non-operative management of rectal cancer with complete clinical 
response to neo-adjuvant chemoradiation seemed anathema, it is now gaining acceptance (1–
5). This approach is relevant for individuals where the potential risks of surgery outweigh the 
benefits, in elderly comorbid patients with rectal cancers, which are increasing as a proportion 
of all cancers diagnosed due to national bowel cancer screening programmes (6, 7). With 
conventional external beam chemoradiotherapy (EBCRT) regimens, the true level of complete 
pathological response is low, occurring in approximately 10–30% of patients who received 
fluoropyrimidine with radiation (8–10). In addition, published data have shown that around 
15–40% of initial complete responders (cCR) will regrow locally and will require surgical 
salvage for cure (8–10). Therefore, there is a need to increase complete response rates, and 
reduce local regrowth to enable more patients to benefit from the watch and wait approach after 
EBCRT.  
At our centre we have adopted the strategy of offering patients escalated doses of radiation 
delivered directly onto the tumor site in an effort to increase the clinical complete response 
(cCR) rate by using a contact X-ray brachytherapy (CXB) boost. The advantage of this 
approach is that it can deliver up to additional 90 Gy of radiation with minimal collateral 
damage to the surrounding normal tissues (11). In this paper, we describe the treatment 
outcomes of this approach from our centre.  
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Methods and materials  
Patient selection 
Eighty three patients were identified from a prospectively maintained institutional database of 
345 consecutive patients with rectal cancer who were referred to our centre for CXB between 
January, 2003, and November, 2012. No ethics approval was necessary for this retrospective 
audit because CXB has been used since 1993 and is not regarded as an experimental treatment 
at our institution. However, approval from our regional audit committee was obtained for this 
retrospective audit (approval number xxx).  
Histological diagnosis of adenocarcinoma was confirmed in all patients prior to treatment. 
Baseline pre-treatment assessment included endoscopy, digital rectal examination (DRE), 
MRI, computed tomography of chest, abdomen and pelvis, and endorectal ultrasound (if MRI 
was not possible due to cardiac pacemaker) undertaken at the patients’ local referring hospitals. 
Initial local T and N staging using TNM (AJCC/UICC.v7) was determined by MRI in 87.9% 
of patients (Table 1). Patients agreed to receive treatment after informed consent and 
counselling. All patients were fully aware that we did not treat all of those who were referred, 
that we only selected suitable individuals for CXB boost, that curative treatment might not be 
possible, and that if there was a residual disease or local regrowth at a later date, salvage surgery 
might be feasible provided they did not have distant metastases, and that they were fit and 
agreeable for surgery. 
 
Inclusion and exclusion criteria 
We include patients with persistent abnormality suspicious of residual cancer either 
endoscopically, on DRE or radiologically which was ≤ 3cm following EBCRT or EBRT for 
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consideration of CXB boost in those patients who were not suitable for surgery or refuse 
surgery.  Individuals who achieved a true clinical complete response (cCR) after EBRT or 
EBCRT were excluded from our present study as this group comprised individuals where there 
was no mucosal abnormality to be seen or felt and hence no target at which to direct the CXB 
boost. Some of those who were referred for consideration of CXB boost had a bulkier residual 
tumor (>3 cm) or a tumor that involved half the rectal circumference (poor responders to 
EBRT/EBCRT). They were offered HDR endoluminal brachytherapy using a rectal applicator 
(Elekta, Stockholm, Sweden) and were also excluded from our study (n=46). Patients who had 
metastatic disease or tumors with regrowth following EBRT/EBCRT were treated palliatively 
(n=86) and were excluded from this analysis. Patients with cT1 tumors who received CXB 
alone (n=17) and both cT1 or cT2/cN0 tumors that were mainly adenomas with a small focus 
of cancer ≤3 cm who received CXB prior to EBRT (n=26) and all other cT1 and cT4 patients 
(n=6) were excluded from our study. In addition, all patients who received CXB within 4 weeks 
of completing EBCRT/EBRT (n=26) were also excluded from our study in order to improve 
the homogeneity of our cohort (Figure 1). Patients with missing data (n=61) were also 
excluded. 
 
External beam radiation dose and schedule 
EBCRT consisted of 45 Gy in 25 fractions over 35 days with concurrent chemotherapy using 
either 5-fluorouracil infusion 1 g/m2 day from day 1–4 in week one and five, or in later period 
of our study, chemotherapy was changed to oral capecitabine 825 mg/m2 twice a day (Monday–
Friday) throughout radiotherapy (n=71). A small number of patients who were not suitable for 
chemotherapy (due to poor renal function) were treated with radiation (EBRT) alone (n=12). 
Patients were assessed at 4–6 weeks after EBRT/EBCRT in the earlier time period of this study 
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but more recently the practice in the UK have changed to assessing patients a little later at 6-8 
weeks. This time point is in line with most international watch and wait protocols (10). All 
patients were discussed again at their local colorectal multidisciplinary team (MDT) meeting 
after their assessment. This included endoscopy, DRE, and restaging MRI scans to evaluate 
their response at their local colorectal units. The interval between EBRT/EBCRT and CXB 
varied, as patients were treated by EBRT/EBCRT at their local cancer units and were 
subsequently referred to our specialist cancer centre for consideration of CXB. In most cases 
the interval was within 4-6 weeks during the earlier period of our study and in the later stages 
it was at 6-8 weeks, with a median of 39 days (range 28–174 days).   
 
Contact X-ray brachytherapy set up, dose, schedule, and rationale 
CXB was delivered using a 50 kVp Therapax (Gulmay, UK) machine between 2003 and 2009, 
and after 2009 by Papillon 50 (Ariane, Derby, UK; Figure 2). The comparison between these 
two machines (12) and the CXB treatment protocol used in this study have previously been 
described (13–16). CXB was administered on an outpatient basis every 2 weeks. At each visit 
30 Gy of 50 kVp X-rays (HVL 0.64 Al, 2.7 mA) was delivered through a rectal treatment 
applicator (size 30, 25, or 22 mm) at a focal source surface distance (FSD) of 29, 32, or 38 mm 
(depending on applicator size chosen). Radiation was targeted straight onto the tumor with a 
5-mm margin under direct vision (Figure 2). Most patients received a total of 90 Gy (surface 
dose) delivered in three fractions (day 0, 14, and 28) over 4 weeks.  
 
 Response assessment and surveillance protocol  
The most intensive monitoring occurred within the first 2 years when the risk of tumor 
recurrence was highest. Patients were seen every 3 months for digital rectal exam (DRE) and 
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sigmoidoscopy. MRI scans were done 4–6 monthly, and computed tomography of chest, 
abdomen, and pelvis was undertaken at 12, 24, and 36 months. A clinical complete response 
(cCR) was defined according to the published criteria as a complete absence of palpable, 
endoscopic or radiological evidence of residual tumor (17). Importantly, the time-point used to 
establish a true clinical incomplete response was 6 months after the last CXB dose, since in our 
experience further regression of tumor is not usually observed beyond this time. If a suspicious 
mucosal abnormality progressed endoscopically, or if induration was felt on DRE, or 
suspicious changes were observed on MRI then patients were referred for immediate salvage 
surgery (ISS) provided they were agreeable and fit for treatment (18). Less importance was 
given to isolated subtle abnormalities on MRI scan or mucosal abnormalities on endoscopy 
that did not change over time (19). These were regarded as static disease and kept under review 
with regular endoscopic and radiological assessments at 3 monthly intervals.  
All patients who remained on the so-called “watch-and-wait” pathway after 6 months were 
reassessed as described above every 3 months for the first 2 years. If any active regrowth of 
tumor was suspected or detected after an initial cCR, the patient was restaged and offered 
delayed surgical salvage (DSS), provided no inoperable distant metastases were detected, that 
they were fit and agreeable for surgery (Figure 1). Throughout the disease-monitoring process, 
clinicians were encouraged not to biopsy the scar if no obvious cancer remained, due to the 
known low negative predictive value of negative histology (19, 20). When cCR was 
maintained, the frequency of assessment was reduced to every 6 months in year 3, and every 
year thereafter for up to 5 years. 
 
Data integrity and statistical analysis 
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Since our data were retrospective and had been accrued over many years, an external 
independent validator was commissioned to ensure its accuracy and integrity. This process 
indicated that 94% of initial data entries were accurate. All identified inaccuracies were 
corrected. The data were analysed using SPSS Version 21 (IBM, Portsmouth, UK). The 
objective of our paper was to report the outcomes of CXB as a boost following EBCRT or 
EBRT.  We choose our main end point as local regrowth in those who had achieved cCR 
following CXB after EBCRT or EBRT. Furthermore, disease-free survival (DFS) was 
estimated using the Kaplan-Meier survival methodology (Figure 3). Univariate and 
multivariate analyses using logistic regression were used to identify possible clinical factors 
associated with treatment response and local regrowth (Table 2).  
 
  
11 
 
Results  
Study group and demographics 
Our institutional database identified 83 patients that fulfilled our inclusion and exclusion 
criteria. The baseline demographics of the study group are shown in Table 1, and their 
outcomes are shown in Figure 1. 
Clinical complete response (cCR)  
A cCR after CXB boost in patients with suspicious residual disease following EBCRT/EBRT 
was observed in 53 patients (63.8%). Univariate logistic regression analysis showed that 
attainment of cCR was not related to pre-treatment performance status (P=0.62), age (P=0.74), 
cT stage (P=0.31), size of tumour (0.27), CXB dose (P=0.82), or external beam treatment 
modality with or without chemotherapy (P=0.56). Importantly, cCR was also not related to pre-
treatment clinical nodal status (P=0.10).  
Clinical incomplete response 
Thirty patients (36.1%) had a clinical incomplete response 6 months after the last dose of CXB. 
Twenty-two (73.3%) patients from this group subsequently underwent surgery as it was 
presumed that they had residual cancer. Interestingly 5 (22.7 %) of these patients actually had 
no residual tumour with pathological stage of ypT0. Eight patients did not proceed to 
immediate salvage surgery (ISS) mainly because of advanced age and comorbidities, however, 
two patients chose not to undergo surgery.   
Local regrowth after initial complete clinical response  
At the study cut-off date, seven (13.2%) patients out of 53 patients who achieved initial cCR 
after CXB boost following EBRT developed either local regrowth or distant relapse. Therefore, 
46 (86.7%) of the 53 patients who achieved cCR had a sustained complete clinical response. 
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The median time for relapse was 16 months (range 4.0–113). Univariate analysis showed that 
tumour regrowth was not associated with pre-treatment performance status (P=0.99), age 
(P=0.69), cT stage (P=0.81), cN stage (P=0.98), original tumour size (P=0.75), treatment 
modality (P=0.10), or CXB dose (P=0.25; Table 2). 
Management of local regrowth  
Of the seven patients (13.2%) who developed tumor regrowth after an initial documented cCR, 
one (1.8%) had distant metastases only. Only 4 patients (7.5%) had local regrowth only and 
two (3.7%) patients had regional nodal regrowth in addition to their local regrowth. All six 
patients with potentially salvageable non metastatic local regrowth (100%), underwent delayed 
salvage surgery (DSS). Interestingly, one (16%) out of the six had no pathological evidence of 
residual tumor (ypT0).  
Distant metastases 
In total, 7 (13.2%) patients developed distant metastases. This included one patient after 
achieving cCR and another two who developed distant metastases after immediate salvage 
surgery (ISS) for residual disease. Two patients relapsed with distant metastases after delayed 
salvage surgery (DSS) for local regrowth. Two patients who had persistent tumour in the initial 
incomplete responder group also developed distant metastases in addition to their local disease 
(Figure 1). Of those who developed distant metastases, three had a metastectomy and the others 
received palliative treatments.    
Disease-free survival  
The Kaplan-Meier probabilities of disease-free survival for the whole group were 70% (95% 
CI 60–80) at 2 years, 59% ( 95% CI 47–71) at 3 years, and 46% at (95% CI 31–61) at 5 years 
(Figure 3). This outcome mainly reflects the elderly nature of this population who also had 
medical comorbidities and in many cases died from causes unrelated to cancer.  
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Toxicities and adverse effects of therapy 
No patient had to stop CXB because of gastrointestinal toxicity. Rectal ulceration (grade 1) 
developed in 30% of cases following CXB, but this usually healed within 3-6 months. Twenty 
three patients (28%) developed bleeding (grade 1) due to telangiectasia, and five (6 %) of the 
83 patients needed argon beam therapy (grade 2) for haemostasis (Common Toxicity Criteria 
Score v 4.0) (21, 22). No patients needed a colostomy due to late gastrointestinal toxicity (grade 
3). No deaths were reported related to CXB. 
Disease status  
At the end of our study period with median follow up of 2.5 years, 69 (83.1 %) of 83 patients 
were free from cancer; this includes those who had salvage surgical treatment (Figure 1). 
Sixteen of the 27 patients who died (60 %) had no documented evidence of residual or recurrent 
cancer, and they died of other causes.  
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Discussion  
Our study constitutes a retrospective analysis of patients from a single institution who 
underwent non-operative watch-and-wait management for rectal cancer. We acknowledge that 
there are limitations, uncertainties and a potential selection bias in our data which could skew 
the initial clinical complete response rate. The difference between this series and the majority 
of other published series is that all patients received an additional boost of CXB in an attempt 
to treat any remaining cancer cells that persisted after EBCRT or EBRT with the aim to reduce 
local regrowth. A further important difference is that the patients included did not have a 
classical clinical complete response because by definition this would mean nothing visible on 
the mucosa or on MRI scan and nothing to feel which in this situation is not possible to target 
CXB. All the patients in our series had a residual mucosal abnormality which meant that they 
did not have a classical clinical complete response following EBCRT/EBRT. Despite our 
patients all having an ‘clinical incomplete response’ following EBCRT/EBRT, we found that 
after CXB, further 63.8% went on to achieved a classical clinical complete response with no 
mucosa abnormalities suspicious of residual disease. Of those who achieved cCR after CXB 
boost, only11% developed a local regrowth and this in turn was salvageable in all 6 non 
metastatic patients.  
Although CXB has been in clinical use for over 80 years, it has not been regarded by many 
clinicians as a standard of care in Europe (23–27) or in the USA (28, 29). Its use has been 
restricted to only a few specialist centres due to decommissioning of the Phillips RT50 machine 
in the 1970s. However, there has since been a revival of interest in CXB with the availability 
of the Papillon 50 machine (Ariane, Alfreton, UK) and now there are 15 centres in Europe 
offering CXB for rectal cancer in suitable cases (14). We find that our referrals constitute 
mostly elderly patients and those that are either unsuitable for surgery or refused surgery. We 
15 
 
are also finding increasing numbers of young and fit patients who wish to explore alternative 
options to radical surgery because of its side effect profile and the likelihood of a stoma. 
As the population is ageing and more patients are been diagnosed with rectal cancer through 
national bowel cancer screening programmes, the number of patients with rectal cancer who 
are suitable and likely to benefit from CXB will increase. Therefore, we need a plan to expand 
the number of centres offering CXB to meet this growing demand in the future. 
A Brazilian research group was one of the first to report the results of a watch-and-wait policy 
for rectal cancer (10). They reported 183 patients who were treated with intensified 
chemoradiotherapy (54 Gy in 28 fractions over 38 days) followed by four cycles of 
chemotherapy and achieved a high (49%) cCR. However, 31% of these patients who achieved 
cCR later developed local regrowth requiring surgical salvage (Table 3). The most comparable 
group to our cohort was reported in the OnCoRe study. The geographic coverage of the patients 
referred to our centre were similar to those patients in the OnCoRe study. The patients in the 
OnCoRe study were those who achieved cCR and were not referred to our centre for CXB 
boost. However, 38% of the 129 patients who just had watch and wait following EBRT needed 
surgical salvage for local regrowth. Meta-analysis of watch and wait trials recently published 
showed lower local regrowths of 15% at a short follow up of 2 years (30). However, the 
majority of patients in the studies reviewed had much earlier stage rectal cancer unlike patients 
in the OnCoRe and our study which included much more advanced staged cancer (70% and 
66.3% T3, respectively) patients with longer follow up of 33 and 29 months, respectively. In 
our series, despite including a heterogeneous group of patients, many of whom were elderly 
with locally advanced disease, six (11%) developed loco regional regrowth, of whom 4 (7.5%) 
had local regrowth only after a median follow up of 2.5 years following an initial cCR. Our 
data, therefore, appear to be very favourable when compared to other published series of non-
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operative management involving standard neoadjuvant protocols using 50 Gy in 25 fractions 
over 5 weeks with fluoropyrimidine, where approximately 15-40% of patients developed local 
tumor regrowth (8–10).  
There are several possible reasons for the high levels of sustained cCR observed in our study 
(Table 3). We believe that dose escalation with CXB boost is an important contributing factor 
(11). The advantage is that any viable tumor cells beneath the surface of the residual mucosal 
abnormality (which is usually ≤20 mm) receive a further very high, yet localized, dose of 
targeted radiotherapy that sterilizes them. The tumor was shaved off layer-by-layer at each 
fortnightly application until the tumor had regressed to its base. The total dose of 90 Gy 
seems quite high, but most of this dose was delivered directly onto the tumor, using low-
energy X-rays with limited range of penetration, so the surrounding normal tissues including 
those at a depth received very little of this radiation dose, thus reducing collateral damage 
which minimised the side effects (15,16).  
The randomized trial Lyon 96-02 provided supportive evidence for improved clinical (24% vs 
2%) and pathological response (57% vs 34%) in favour of CXB boost in addition to EBRT for 
more advanced bulky stage T2 and T3 rectal cancers (27). More recently, histological data 
following EBRT for earlier staged cT1, cT2, and cT3a tumors have been reported from two 
independent trials. One study from the UK on cT1 and cT2 rectal cancers showed 32% pCR 
after 8–10 weeks following short course radiotherapy (SCRT), and a similar Dutch study 
reported 44% pCR following EBCRT for cT1, cT2, and cT3a tumors (31,32). There was 
histological evidence of residual tumor in 68% and 56% of patients in both trials. Transanal 
endoscopic microsurgery (TEMS) provided the histological status following either neo-
adjuvant SCRT or EBCRT. Our data suggest that the residual disease that remained could be 
sterilized by CXB to reduce local regrowth down to 11%. Our data concur with those from a 
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published prospective study on a well-defined group of patients in a single centre in Hull (UK) 
treated under a strict protocol, which showed reduction in local regrowth to 12% (n=5) when 
CXB boost was offered in addition to EBRT (32). Moreover, a recent publication from Nice 
(France) showed 11% predicted local regrowth at 5 years in patients with more advanced 
cT2/cT3 tumors treated by combination of EBCRT at a higher dose of 50 Gy in 25 fractions 
over 5 weeks and CXB 90 Gy in three fractions (33). Both these studies used a CXB boost 
similar to that received by our patients, but both were prospective studies involving patients 
treated under strict protocol in single institutions. Both studies showed low rates of local 
regrowth similar to our series, which suggests that CXB is a significant contributor to this 
observation (Table 3). We are assessing this hypothesis further in an ongoing European 
multicentre phase 3 randomized trial which started 2 years ago and so far 45 patients have been 
randomized.  
We believe another important clinical finding from our results is that most of our patients (16 
of the 27 patients [60%]) who died had no documented evidence of cancer (i.e. they died from 
other medical causes). As such, our data highlight the importance of competing oncological 
outcomes against physiological risk involved in decision making for rectal cancer, in comorbid 
and elderly patient groups who are increasing in number due to an ageing population (27). 
Furthermore, in patients who had an initial cCR and subsequently developed local and     
regional regrowth, delayed salvage surgery was possible in the all of six patients (100%) who 
did not have distant metastatic disease (18). These results mirror those from other specialist 
centres where reported surgical salvage rates have been around 90% (9, 10, and 30).  
There are further limitations in our study as our data was a retrospective analysis of patients 
treated over many decades with all its drawbacks. We also did not compare our outcomes with 
patients who received radical surgery, which is the current gold standard treatment. However, 
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the OnCoRe study did perform this. It compared the oncological outcomes of 129 patients 
managed by watch-and-wait (38% needed surgical salvage for local regrowth) with a 
propensity-score matched group of patients that underwent index radical surgery and showed 
no difference in their survival outcomes (9).  
We acknowledge that our follow up was relatively short and we have also not included outcome 
data concerning bowel function. However, we are in the process of formally prospectively 
recording functional data for our patients through a national data set as recommended by NICE 
(National Institute of Health and Care Excellence). In addition, there was a review of acute and 
long term toxicities of CXB by NICE and their findings were published as IPG 532 (35). Their 
findings of acceptable safety and toxicity profiles in patients not suitable for surgery were 
consistent with our experience. 
We also accept that our data do not form part of a formal clinical study, that our patients were 
not randomized, and that this was essentially a retrospective observational study with all its 
limitations. This is because until recently non-operative management was deemed anathema to 
conventional treatment for rectal cancer and very few patients were referred for CXB boost 
after EBRT/EBCRT. We aim to rectify these issues in the trial which is a European multi-
centre phase 3 randomized trial, for which we have started recruiting patients. The primary 
endpoint is organ preservation with local control at 3 years (36). 
Conclusions 
Our data with all its limitation and uncertainties have shown that patients with clinical 
incomplete response to ECBRT/EBRT can still achieve a clinical complete response after CXB 
boost. Of these who achieved cCR, only 11% developed a local regrowth and this percentage 
is low when compared to other series. All 6 patients with non-metastatic local regrowth could 
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be salvaged. We do, however, accept that this technique ideally needs to be assessed in a 
clinical trial of which one is under way. We do believe that CXB is particularly pertinent for 
older or comorbid patients with rectal cancer who are not suitable for surgical salvage, or for 
younger stoma-averse patients who wish to avoid surgical salvage (if possible) in the event of 
local regrowth following EBCRT/EBRT. 
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Figure legends 
 
Table 1: Patient characteristics 
Table 2: Prognostic factors related to treatment clinical outcomes 
 
Table 3: Comparative local regrowth rates following different treatment modalities 
Figure 1: Patient care pathway flow chart  
Figure 2: Contact X-ray brachytherapy treatment position and schematic diagram 
Figure 3: Disease-free survival  
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Table 1: Patient characteristics  
           N                      % 
Age median (range)            72 years (36-87) 
Sex Female 25 30.1% 
Male 58 69.9% 
Performance status 0 35 42.2% 
1 34 41.0% 
2 9 10.8% 
3 3 3.6% 
Not Known 2 2.4% 
Differentiation Well 3 3.6% 
Moderate 58 69.9% 
Poor 1 1.2% 
Not Known 21 25.3% 
Tumour stage cT2 28 33.7% 
cT3 55 66.3% 
Nodal stage cN0 38 45.8% 
cN1 32 38.6% 
cN2 12 14.5% 
Not Known 1 1.2% 
Metastases stage M0 83 100% 
Tumour size 
≤3cm 
47 56.6% 
>3 cm 
23 27.7% 
Not Recorded 
13 15.7% 
Distance from anal 
verge (cm) 
<7 cm 
61 73.5% 
7-11 cm 
16 19.3% 
Not Recorded 
6 7.2% 
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 Table 2: Prognostic factors related to treatment response and local regrowth 
 
 
 
 
Treatment response 
 
Local regrowth 
 
 
Prognostic factors N HR 95% CI P HR 95% CI 
 
     P 
 
Performance status 0 35 Ref  0.62 Ref  0.99 
1 34 0.43 0.14-1.35 0.62 0.08-4.64 
2 9 1.19 0.2-6.94 0.00 0-0 
3 3 1.22 0.07-21.03 0.00 0-0 
Not known 2 1.09 0.03-42.78 0.00 0-0 
Age group <70 33 Ref  0.74 Ref  0.69 
70-79 30 0.66 0.2-2.18 2.49 0.3-20.38 
80-89 20 1.03 0.24-4.36 1.41 0.08-24.77 
Tumour stage cT2 28 Ref  0.31 Ref  0.81 
cT3 55 1.87 0.56-6.18 0.76 0.08-6.98 
Nodal stage  cN negative 38 Ref  1.00 Ref  0.98 
cN positive 44 1.01 0.32-3.19 1.25 0.11-13.58 
Not known 1 0.00 0-0 0.00 0-0 
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Distant from anal verge    <7 cm 61 Ref  0.32 Ref  0.63 
7-11 cm 16 0.43 0.1-1.84 3.34 0.28-39.96 
Not known 6 0.23 0.02-2.85 0.00 0-0 
Tumour size ≤3cm 31 Ref  0.27 Ref  0.75 
>3 cm 34 0.61 0.19-2  0.39 0.03-4.9  
Not recorded 18 1.99 0.46-8.62  0.88 0.06-12.91  
Treatment modality Chemoradiation 71 Ref  0.56 Ref  1.00 
RT alone 12 0.58 0.1-3.51 0.00 0-0 
Papillion total dose ≤90 Gy 79 Ref  0.82 Ref  0.25 
>90 Gy 4 0.74 0.05-9.99 8.65 0.22-347.01 
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Table 3 Comparison of initial response and local regrowth after cCR 
 
            Study 
 
   n 
 
      Treatment modality 
 
Initial Response (%) 
 
 Local regrowth (%) 
 
Habr Gama (10) 
 
  183 
 
EBCRT 45Gy +EBRT boost 9Gy 
 
       90/183 (49) 
 
 28/90   (31 at 5 years) 
 
Appelt ( 2) 
 
    51 
 
EBCRT 60Gy + HDR 5Gy 
               
 
       40/51 (78) 
 
 9/40     (25.9 at 2 years) 
 
Renehan (9) 
 
  129 
 
EBCRT 45Gy  
 
            NA   
 
 44/129  (38 at 3 years) 
 
Gerard (34)           
 
    45 
 
EBCRT 50Gy + CXB 90 Gy               
 
       43/45 (98) 
 
 3/43      (11 at 5 years) 
 
Dhadda (33) 
 
    42 
 
EBCRT 45 Gy + CXB 90 Gy 
 
            NA 
 
 5/42       (12 at 2 years) 
 
 Present study 
 
  83 
 
EBCRT 45Gy + CXB 90 Gy 
 
      53/83 (63.8) 
 
 6/53 ( 11.3 at 2.5 years) 
 
Abbreviations HDR =High dose rate brachytherapy; NA=not available. 
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Figure 1 
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Figure 2 
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Figure 3 
 
 
